What is FEIBA hemophilia?
What is FEIBA? FEIBA is an Anti-Inhibitor Coagulant Complex approved for use in hemophilia A and B patients with inhibitors for: Control and prevention of bleeding episodes. Use around the time of surgery. Routine prophylaxis to prevent or reduce the frequency of bleeding episodes.
What cause acquired hemophilia?
Acquired hemophilia occurs when the body’s immune system attacks and disables a certain protein that helps the blood clot. About half of the cases are associated with other conditions, such as pregnancy, autoimmune disease, cancer, skin diseases, or allergic reactions to medications.
What does FEIBA stand for?
FEIBA stands for Factor Eight Inhibitor Bypassing Activity.
Is FEIBA a bypassing agent?
FEIBA (factor VIII inhibitor-bypassing activity), an activated prothrombin complex concentrate (aPCC), and NovoSeven, recombinant factor VIIa (rFVIIa), are used as hemostatic bypassing agents in treating patients with inhibitors.
What factors are in FEIBA?
FEIBA contains mainly non-activated factors II, IX, and X and mainly activated factor VII. It contains approximately equal unitages of factor VIII inhibitor bypassing activity and prothrombin complex factors. In addition, the preparation contains 1-6 units of factor VIII coagulant antigen (F VIII C: Ag) per mL.
How much is FEIBA?
FEIBA is an anti-inhibitor coagulant complex with the capacity to provide FVIII inhibitor bypassing activity. According to a 2018 analysis from the Institute for Clinical and Economic Review, treatment of a single bleeding episode with FEIBA can cost $50,000 or more.
Is acquired hemophilia hereditary?
Hemophilia A and B are inherited as X-linked recessive genetic disorders, while hemophilia C is inherited as an autosomal recessive genetic disorder. Hemophilia A and B are mostly expressed in males, but females can also be affected. Hemophilia C affects males and females in equal numbers.
Is acquired hemophilia curable?
If left untreated, acquired hemophilia can be very serious and life-threatening. However, it is easily treated once diagnosed with immunosuppressive drugs and injections of clotting factor.
What is the difference between KCentra and FEIBA?
FEIBA® is current formulary activated prothrombin complex concentrate (aPCC) product. KCentra® is current formulary prothrombin complex concentrate (PCC) product. Kcentra™ contains clotting factors II, VII, IX and X. It contains heparin and use should be avoided in patients where heparin is contraindicated.
Does FEIBA contain heparin?
It contains no heparin. Reconstituted FEIBA contains 4 mg of trisodium citrate and 8 mg of sodium chloride per mL. FEIBA is manufactured from large pools of human plasma.
What clotting factors are in FEIBA?
FEIBA provides several different clotting factors—mainly unactivated factors II, IX, and X; and mainly activated factor VII—and works at different sites in the clotting system. This restores thrombin generation and helps with the formation of the fibrin clot, which stops bleeding.
How do you give FEIBA?
Base the dose and frequency of FEIBA on the individual clinical response. Clinical response to treatment with FEIBA may vary by patient and may not correlate with the patient’s inhibitor titer. Do not exceed a single dose of 100 units per kg body weight and a daily dose of 200 units per kg body weight.
Is FEIBA a blood product?
Factor eight inhibitor bypassing activity (FEIBA) is currently approved for use in this country for the treatment of patients with Hemophilia and inhibitors at a dose of 50-100 units/kg….FEIBA and Use of Blood Products in Cardiac Surgery (FEIBA)
| Last Update Posted: | July 14, 2020 |
| Last Verified: | July 2020 |
How rare is acquired hemophilia?
Acquired hemophilia is rare, with an overall incidence of 1.5 per million per year.
How I treat acquired hemophilia?
A variety of additional immunosuppressive agents have been used to treat acquired hemophilia including cyclosporine A, azathioprine, vincristine, mycophenolate mofetil, and 2-chlorodeoxyadenosine.
What is the average life expectancy of a person with hemophilia?
Estimated median life expectancy of patients with hemophilia was 77 years, 6 years lower than the median life expectancy of the general Dutch male population (83 years).
Is Feiba a aPCC?
FEIBA NF and VH are considered aPCC products because they contain mostly activated factor VII along with mainly non-activated factors II, IX, and X.
Is FEIBA a APCC?
When do you use FEIBA?
INDICATIONS AND USAGE FEIBA is an Anti-Inhibitor Coagulant Complex indicated for use in hemophilia A and B patients with inhibitors for: • Control and prevention of bleeding episodes • Perioperative management • Routine prophylaxis to prevent or reduce the frequency of bleeding episodes.
Does factor VIII inhibitor bypass activity (feiba) have a role in Aha?
Factor VIII inhibitor bypass activity (FEIBA) is a recommended first-line bypassing agent for bleeding episodes in patients with acquired haemophilia A (AHA). Due to the low incidence of AHA, available clinical data on FEIBA treatment are limited. The study aim was to delineate practice patterns in …
What is acquired hemophilia?
Acquired hemophilia is a rare condition characterized by the development of neutralizing or inactivating autoantibodies to FVIII in patients with previously normal FVIII levels. An incidence of 0.2–1 patient per million persons per year has been reported (Shapiro and Hultin 1975; Lottenberg et al 1987; Holme et al 2005).
Does feiba improve thrombin generation?
FEIBA: mode of action Testing plasmas deficient in different coagulation factors using TGA, Turecek et al showed that FEIBA improves thrombin generation in all plasmas, except FV-deficient plasma (Turecek et al 1999, 2003).
Can feiba cause blood clots?
Blood clots that block blood vessels and their effects have been reported during post-marketing surveillance following infusion of FEIBA, particularly following administration of high doses (above 200 units per kg per day) and/or in patients at risk for forming blood clots. If you experience any of these side effects, call your doctor right away.